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What Lies Beyond the Emergency Department Doors?*Michael E. Farkouh, MD, MSC,y Pamela S. Douglas, MDzSEE PAGE 16W ith >8 million emergency department(ED) visits annually in the United Statesand a reported 2% of patients discharged
from the ED with a missed acute coronary syndrome,
the optimal management of acute chest pain in the
ED is a dilemma faced by many clinicians (1). Risk
stratiﬁcation on the basis of the initial history, phys-
ical examination, electrocardiogram, and troponin
measurement is essential early in the triage process.
For patients with low to intermediate risk for short-
term death and myocardial infarction (MI), the evalu-
ation is focused on identifying those who can be safely
discharged from the ED after an observation period,
with or without a noninvasive study to evaluate
for ischemia (stress test) or coronary artery obstruc-
tion (coronary computed tomography angiography
[CCTA]). With the advent of high-sensitivity troponins
(hsTn), the ability to rule outMI in the ED has improved
(2). Previous protocols utilized creatine kinasemyocar-
dial band or regular troponin. Therefore, strategies
incorporating hsTn have not yet been widely studied.
However, there is also a second goal of the ED eval-
uation: risk stratiﬁcation for future events. Although
clinical studies of chest pain algorithms and in-
vestigations have conﬁrmed that low- to intermediate-
risk patients are generally at exceedingly low risk in
terms of short-term death and MI (3,4), to date, all of
the trials have been underpowered for hard events.
Therefore, decisions on the next steps after acute MI is
ruled out are usually on the basis of clinician experi-
ence, health care system issues, or societal factors.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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paper to disclose.In this issue of the Journal, Dedic et al. (5) report on
the BEACON (Better Evaluation of Acute Chest Pain
with Coronary Computed Tomography Angiography)
trial, a multicenter study of chest pain evaluation inwhich patients were randomized to early CCTA
compared with standard optimal care after hsTn had
ruled out MI in the ED. The trial was composed of 500
patients, with a mean age of 54 years, who had pre-
sented with low- to intermediate-risk acute chest pain
and were followed for 30 days. As expected, there was
no difference in mortality (with only 1 death overall) or
in major adverse cardiac events. As a result of power
issues, the primary endpoint of the trial was the need
for coronary revascularization. There was a 2% excess
of procedures in the CCTA arm (9% vs. 7%, p ¼ 0.40),
but the investigators had powered the trial to detect a
9% absolute difference in revascularization rates
between the 2 arms if CCTA was to be considered
superior. There were also no differences in the
pre-speciﬁed key secondary outcome measures of
discharge from the ED, length of stay, and repeat ED
visits. The only clear advantage of CCTA appeared to be
in the reduction of costs of about 34%due to signiﬁcant
reductions in outpatient testing after the index ED
visit. In the hsTn era, we anticipate that such surrogate
outcomes of efﬁciency of care and optimal use of
resources will become increasingly important.
The BEACON trial brings to light some important
observations regarding trials in this ﬁeld. Like many
trials of strategies for chest pain in the ED, the pri-
mary endpoint was evaluated only within 30 days.
When considering short-term surrogate endpoints,
2 key trials have demonstrated advantages for a
CCTA-guided approach (3,4). For the CCTA group,
both the more recent ACRIN-PA (American College
of Radiology Imaging Network-Pennsylvania) and
ROMICAT-II (Rule Out Myocardial Infarction using
Computer Assisted Tomography II) trials showed that
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28there was a 25% to 35% higher rate of discharge from
the ED and a 7-h shorter length of stay. In contrast to
the BEACON trial, ROMICAT-II found increased
downstream testing, although without reducing sub-
sequent ED visits in the CCTA group. So, what are the
determinants of short-term outcome that will best
inform practice, and from the data at hand, can we
determine the optimal strategy to be employed? The
alternatives to CCTA remain a functional study with
standard treadmill exercise tests, stress myocardial
perfusion imaging, or stress echocardiography. For
the most part, the reasons for choosing among these
tests appear to be very center-speciﬁc, and depend
upon expertise and availability of testing. In addition,
we must look at health care systems. Patients in the
BEACON trial were generally evaluated in the ED with
a discharge plan for subsequent follow-up in desig-
nated chest pain clinics within 48 to 72 h. By contrast,
due to limitations in securing and adhering to outpa-
tient follow-up visits, there is a greater likelihood in
the United States that a more advanced work-up is
done in the acute setting (6). Opportunities to save on
resource utilization and costs can also drive the next
steps. The European BEACON trial was associated
with cost savings, whereas the American ROMICAT-II
study showed no signiﬁcant cost savings up to 30
days. There are also societal issues that play a role in
what is carried out in the ED. The fear of litigation is
more of a concern to ED physicians in the United
States, leading to a perceived greater need to evaluate
the patient more thoroughly before discharge (6).
Another important issue is the long-term manage-
ment of patients beyond the ﬁrst 30 days. In one
randomized comparison with standard exercise stress
testing, CCTA was associated with both reduced ED
visits and cardiac admissions (7), whereas in another,
there was no difference (8). What is becomingapparent is that the visit to the ED affords the
opportunity to optimize medical risk factor care,
including antiplatelet agents, lipid-lowering agents
including statins, and management of hypertension,
as well as educating the patient on the aforemen-
tioned. These interventions will have long-term
consequences. One advantage of CCTA is that by
characterizing plaque burden and the nature of pla-
que, we may be able to have better adherence to
secondary prevention guidelines (9), which should
improve long-term cardiovascular outcomes.
Given the success of ED rapid triage algorithms
using imaging, biomarkers, or both, the ﬁeld is now
moving beyond the issue of safe discharge for patients
at low to intermediate risk, to long-term prevention of
CV events and efﬁcient use of resources. Long-term
management of these patients to reduce resource
utilization and return visits to the ED and to provide
better cardiovascular outcomes needs further evalua-
tion in long-term studies. We encourage all clinical
investigations of chest pain in the ED to follow patients
long term so that we can better understand the true
impact on patient health and costs. As accessibility
increases and radiation doses are lowered, CCTA-
based protocols continue to be a viable, and often
attractive, option, but theymay not be the only option.
We call for a collaborative effort between ED physi-
cians and the cardiovascular community to incorpo-
rate these data into a tailored approach to short- and
long-term management of low- to intermediate-risk
patients that best suits the needs of their patients
and the capabilities of their health care systems.
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